Sumanta K. Pal
苏曼塔·帕尔
MD
Co-Director, Kidney Cancer Program; Professor, Department of Medical Oncology肾癌项目联合主任；医学肿瘤学系教授
👥Biography 个人简介
Sumanta K. Pal, MD is Co-Director of the Kidney Cancer Program at City of Hope and a leading investigator in non-clear cell RCC, genomic biomarkers, and novel therapeutic strategies for advanced kidney cancer. He has led pivotal studies of cabozantinib, MET-targeted therapies, and IO combinations in papillary and sarcomatoid RCC, and is a prominent voice in translational kidney cancer research at international meetings.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Non-Clear Cell RCC Therapeutic Development
Led prospective clinical trials specifically enrolling non-clear cell RCC patients—including SWOG S1500 comparing systemic therapies in papillary RCC—addressing a historically underserved population excluded from major pivotal RCC trials.
Sarcomatoid RCC and IO Benefit
Conducted landmark analyses demonstrating that sarcomatoid differentiation in RCC is a strong predictive biomarker for response to nivolumab plus ipilimumab, helping identify a subset of patients with greatest IO benefit.
Cabozantinib in Non-Clear Cell and Second-Line RCC
Contributed to development and subgroup analyses of cabozantinib in non-clear cell RCC histologies, and led trials exploring cabozantinib-based combinations in treatment-naive and previously treated settings.
Genomic Landscape of Advanced RCC
Performed comprehensive next-generation sequencing analyses characterizing the mutational landscape of metastatic RCC including BAP1, PBRM1, and SETD2 alterations and their associations with clinical outcomes and immunotherapy response.
Representative Works 代表性著作
SWOG 1500: Cabozantinib versus Sunitinib versus Crizotinib versus Savolitinib in Papillary RCC
Journal of Clinical Oncology (2021)
Randomized phase II trial (SWOG S1500) demonstrating cabozantinib improved PFS versus sunitinib in papillary RCC, providing the first prospective evidence supporting cabozantinib use in this histology.
Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: Molecular Determinants and Treatment Paradigm
Journal of Clinical Oncology (2020)
Comprehensive analysis demonstrating that sarcomatoid RCC has a distinct genomic profile enriched for CDK11B mutations and derives preferential benefit from nivolumab plus ipilimumab.
Genomic Profiling of Advanced Renal Cell Carcinoma
European Urology (2022)
NGS characterization of 1,000+ advanced RCC patients identifying actionable alterations and associations between tumor mutational burden, PD-L1 expression, and immunotherapy outcomes.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 苏曼塔·帕尔 的研究动态
Follow Sumanta K. Pal's research updates
留下邮箱，当我们发布与 Sumanta K. Pal（City of Hope Comprehensive Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment